IC
ELDN icon

Ikarian Capital’s Eledon Pharmaceuticals ELDN Stock Holding History

Ikarian Capital’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,000,221
Closed -$2.71M – 178
2025
Q2 		$2.71M Sell
1,000,221
-25,000
-2% -$75K 0.52% 55
2025
Q1 		$3.48M Sell
1,025,221
-101,416
-9% -$417K 0.43% 54
2024
Q4 		$4.64M Buy
+1,126,637
New +$4.44M 0.63% 42
2023
Q3 		– Sell
-221,830
Closed -$304K – 157
2023
Q2 		$304K Hold
221,830
– – 0.05% 105
2023
Q1 		$524K Hold
221,830
– – 0.12% 94
2022
Q4 		$515K Hold
221,830
– – 0.12% 55
2022
Q3 		$612K Sell
221,830
-140,707
-39% -$448K 0.12% 78
2022
Q2 		$884K Hold
362,537
– – 0.16% 85
2022
Q1 		$1.43M Buy
362,537
+17,959
+5% +$69.6K 0.19% 85
2021
Q4 		$1.52M Hold
344,578
– – 0.23% 81
2021
Q3 		$2.13M Sell
344,578
-5,422
-2% -$37.9K 0.15% 122
2021
Q2 		$2.77M Buy
350,000
+100,000
+40% +$943K 0.22% 105
2021
Q1 		$2.68M Buy
+250,000
New +$3.77M 0.09% 182

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Ikarian Capital's ELDN Position: Q3 2025 in Review

Ikarian Capital sold out of Eledon Pharmaceuticals (ELDN) in Q3 2025, closing a stake of 1,000,221 shares — an estimated $2.71M sold.

Ikarian Capital first reported a position in ELDN in Q1 2021 and held it in 13 quarters. The position peaked at $4.64M in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q3 2025.

  • Ikarian Capital reported no remaining Eledon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ikarian Capital sold 1,000,221 Eledon Pharmaceuticals shares in Q3 2025, an estimated $2.71M.
  • Ikarian Capital first reported a position in Eledon Pharmaceuticals in Q1 2021 and held it in 13 quarters.
  • Ikarian Capital's Eledon Pharmaceuticals position peaked at $4.64M in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.